The higher abundance of Bifidobacterium longum in the intestinal microbiota has been linked to a favorable response in patients with hormone receptor-positive (HR+) HER2-negative metastatic BC who received cyclin-dependent kinase (CDK)4/6 inhibitors as part of their endocrine therapy [33]. This evidence concerns the gene ERBB2 and breast cancer.